Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA. His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc. He has participated at more than two hundreds reputed international conferences, seminars, congresses, symposiums and forums around the world as yet. Also, he possesses many published articles in Science Citation Index (SCI)/International Scientific Indexing (ISI) Journals. It should be noted that he has visited many universities or scientific and academic research institutes in different countries such as United States, United Kingdom, Canada, Australia, Scotland, Ireland, Netherlands, Belgium, Denmark, Greece, Russia, Estonia, Turkey, France, Swiss, Germany, Sweden, Italy, Austria, Hungary, Poland, Brazil, Spain, Portugal, Mexico, Japan, Singapore, Malaysia, Thailand, Taiwan, South Korea, China, India, Qatar, United Arab Emirates, etc. as research fellow, sabbatical and volunteer researcher or visitor and so on heretofore. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than eight hundreds reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international journals, books and publishers. Hitherward, he is a member of more than two hundreds reputed international academic–scientific–research institutes around the world. In addition, he is member of the Nobel committee for Chemistry. It should be noted that he is currently the President of American International Standards Institute (AISI), Irvine, California, USA and also Director of the BioSpectroscopy Core Research Laboratory at California South University (CSU), Irvine, California, USA.
Oncology, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells
Professor Diana Anderson currently holds the Established Chair of Biomedical Sciences at the University of Bradford, UK. She obtained her first degree in the University of Wales and second degrees in the Faculty of Medicine, University of Manchester. After tutoring at the University of Sydney, Australia, she became a research worker in the Department of Cancer Studies at the University of Leeds and at the Paterson Laboratories, Christie Hospital, Manchester. In 1974, she was appointed as Head of Mutagenesis Studies at ICI’s Central Toxicology Laboratory. Professor Anderson joined BIBRA International in 1981 as Head of Genetic and Reproductive Toxicology and became Assistant Director and Group Forum Co-ordinator in 1987. In 1992, she became Senior Associate and Co-ordinator of External Affairs at BIBRA. She has served on the editorial board of 8 international journals plus 2 on line journals, has over 450 publications, has edited/authored 8 books and guest-edited 9 special issues of 4 international journals. She was a Series Editor of books in ‘Current Toxicology’ for John Wiley and Sons and is currently Editor–in-Chief for the Book Series ‘Issues in Toxicology’ for the Royal Society of Chemistry. She is an active Committee member and has been Vice-President of the Institute of Biology. She has successfully supervised 30 post-graduates [26 PhD, 2 MPhil and 2 MSc (Res) students] and is currently supervising 5 other PhDs and has managed several post–doc positions. She has been external examiner for 29 PhDs and was External Examiner for the Dept. of Genetics, University of Wales, Swansea. She has been invited to speak at many international meetings and chair many symposia. She has helped establish new research laboratories in India and Korea under the auspices of the British Council and UNIDO. Funded by various international agencies, scientists from America, Australia, the Czech Republic, Italy, India, Iran, Korea, Poland, Serbia, Spain and Turkey have received training under her supervision. She has organised both national and international meetings and is/was a member of various national (e.g. MRC Advisory Board, Veterinary Products Committee) and was of international committees, including the Chairman of the Scientific Committee of the Foundation of International Association of Environmental Mutagen Societies and the European Union Scientific Committee for Animal Nutrition (SCAN). She has hosted and participated in 56 meetings for WHO/IPCS. In 2011, she won a prize as an Enterprise Fellow from Yorkshire Forward. In 2015, she won the Vice Chancellor’s award at the University of Bradford for Outstanding Achievement.
Cancer, oxygen radicals, human biomonitoring, unbalanced precursor pools, dietary imbalance, male-mediated developmental defects, nanotoxicology, general toxicology
Ziding F completed his PhD from Cornell University. He is a professor, Kathryn O’Connor Research Professor, and Section Chief of Early Detection and Biomarkers in the Department of Biostatistics, and Co-Director of the Center for Global Cancer Early Detection at UT MD Anderson Cancer Center. He has been the Principal Investigator of the Data Management and Coordinating Center (DMCC) for the Early Detection Research Network (EDRN) since 2000, and of the Coordinating and Data Management Center for the Consortium to Study Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) since 2015. He also has a grant from NCI to incorporate biomarkers to improve lung cancer risk prediction model using PLCO specimens and data. He is the coordinating center PI for a study funded by Cancer Prevention Research Institute of Texas (CPRIT) to establish a large cohort of cirrhosis patients to improve early detection of HCC.
Dr Sergey Suchkov, MD, PhD. Professor in Immunology & Medicine. Personal: Born 11 January 1957, Astrakhan, Russia. divorced; two sons. Education: MD, Astrakhan State Medical University, Russia, 1980; PhD, I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, 1985; Doctor Degree, National Institute of Immunology, Russia, 2001. Positions held: Post Doc Research Associate, Institute of Medical Enzymology, 1985-87; Senior Research Associate, Koltzov Institute of Developmental Biology, USSR Academy of Sciences, 1987-89; Head of the Lab of Immunology and Immunobiotechnology, Helmholtz Eye Research Institute in Moscow, 1989-95; Trainee, Laboratory of Immunology, NEI, Bethesda, MD, USA, NIH and Laboratory of Immunology, Wills Eye Hospital, Philadelphia, USA, as well as at some of the British Universities on the invitation of the Royal Society for Immunology, 1989; Chairman, Department for Clinical Immunology, Moscow Clinical Research Institute and the Immunologist-in-Chief of the Moscow Regional Ministry of Health, 1995-2004; Executive Secretary-in-Chief of the Editorial Board, Biomedical Science International journal, 1993-1996; Professor in Medicine and Immunology, I.M. Sechenov First Moscow Medical University and Faculty Chairman & Director of the Department of Preventive, Personalized and Translational Medicine, A.I.Evdokimov Moscow State University of Medicine & Dentistry. Honours: Secretary General, United Cultural Convention, Cambridge, UK. Memberships: New York Academy of Sciences, USA; European Association for Predictive, Preventive and Personalized Medicine, Brussels; American Association for Research in Vision and Ophthalmology; International Society for Eye Research; EPMA Journal, Personalized Medicine Universe, Open J.Autoimmunity and American J.Cardiovascular Res. Editorial Boards; All-Union (from 1992 - Russian) Biochemical Society; All-Union (from 1992 - Russian) Immunological Society.
University of TexasKen H. Young, MD PhD is an Associate Professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center. He was Medical Director of Hematology at the University of Wisconsin School of Medicine and University East & West Clinic Laboratories, overseeing the laboratories at the University of Wisconin Hospital and Clinics Core Laboratory. He received his PhD from University of Lund School of Medicine and completed his MD training from Oregon Health Science University. He is board certified in Anatomic and Clinical Pathology and Hematopathology.
His interests are to characterize molecular defects in patients with leukemia and lymphoma by using gene expression profiling, immunophenotypic method, methylation-microRNA-CGH arrays and current NGS molecular technologies with particular interest in tumor suppressor genes, oncogenes, p53 and NF-kB pathways. He has worked extensively on molecular diagnostics for human cancer and has obtained several novel discoveries valuable to predict treatment response, clinical outcome and survival in cancer patients.
ACHOUR Radhouane is associate professor at faculty of medicine of Tunis-Tunisia; He has published many basic and clinical articles in relation to gynecology and obstetrics. , his research interests include Rare Diseases in gynecology and prenatal diagnosis. He serves as associate professor, Emergency Department of Gynecology and Obstetrics in maternity and neonatology center Tunis Tunisia. He also serves as member of the editorial team for: Asian Pacific Journal of Reproduction, the Global Journal of Rare Diseases, Journal of Neonatal Biology, Current pediatric research, Obstetrics and Gynecology: Open access, Pediatrics and Health Research and Member of the Science Advisory Board.
Gynecology and Obstetrics
Michael Retsky (PhD in Physics from University of Chicago) made a career change to cancer research thirty years ago. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. Retsky is Editor with Romano Demicheli of a Springer-Nature book published July 2017 (Perioperative Inflammation as Triggering Origin of Metastasis Development). After diagnosis of stage IIIc colon cancer in 1994, he was the first person to use what is now called metronomic chemotherapy. He is a founder and was on the Board of Directors of the Colon Cancer Alliance.
He has published 70 papers in physics and cancer.
Prof Blumenfeld has completed hi? MD from the Hebrew university and Hadassah med school in Jerusalem in 1973. Residency in Ob.Gyn- Rambam Med Ctr in Haifa. Fellowship in reproductive endocrinology at UCSF, 1983-85. He is associate Prof at the Technion- Israel Institute of Technology, and director of women health ctr, Meuhedeth med services, Haifa, Israel. Editor in chief of Clin. Med. Insight-Reprod Health, and on the editorial board of JCEM, Fert & Steril., Euro J. Ob Gyn Reprod Biol, and 18 additional peer reviewed journals and has published 218 papers in peer reviewed journals. His main interest: fertility preservation, ART/IVF, POI/POF, PCOS, AMH/Inhibin/Activin.
Associate Professor, Division of Head and Neck Cancer Research, Department of Otolaryngology-Head and Neck Surgery, Department of Oncology, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Head and Neck Cancer
Andrey Sorokin graduated from the St. Petersburg State University and received his Ph.D. from the Institute of Cytology Academy of Sciences of Russia in 1981. A. Sorokin is a Head of the Laboratory at the Medical College of Wisconsin, where he is holding the position of Full Professor of Medicine with secondary appointments at Department of Physiology and Department of Microbiology & Immunology. He has published more than 100 papers in reputed journals and is serving as an editorial board member of a number of journals including Frontiers in Renal and Epithelial Physiology.
Prof. Yongxiang Zhao is the innovative leading talent of National "Ten Thousand Talent Programme", the director of the National Center for International Research of Biological Targeting Diagnosis and Therapy, the moderator of the BIT’s 5th World Gene Convention Keynote Forum---Nobel Laureate Forum, the national talented person of “New Centuary National Hundred, Thousand and Ten Thousand Talent Project”. The leader of National Innovative Talent Promotion Program---Innovation Team of National Key Fields, the leader of National Innovation Team for the Changjiang Scholars Project, the expert of National "Ten Thousand Talent Programme" and “Changjiang Scholars Programme”, the expert of National Natural Science Foundation of subject review group, the standing director of Chinese Immunological Society, the member of Chinese Medical Association Professional Committee of Clinical Precision Medicine, the expert of National Science and Technology Award assessment, the member of Chinese medical science and Technology Award Evaluation Committee, the member of Gene Therapy Branch of Chinese Medical Association. The reviewers and editorial board members of multiple SCI journals such as Nature. He has taken charge of 14 national science and technology major projects and 16 provincial and ministerial projects.
Focus on biological targeting diagnosis and therapy for tumor, including: 1?The key targets and mechanism of malignant tumor’s occurrence and progress. 2?Homologous antitumor vaccines. 3?Research and development of heterologous oncolytic biological drugs. 4?Research and development of tumor biotargeted diagnostic reagents. Based on these research results, 79 SCI papers have been published in international journals, such as Nature Biotechnology (IF=41.67). One International Academic Award, one ministerial and provincial first prize, thirty national patents and two authorized international PCT patents. Future Outlook: It is believe that the new anti-cancer cell vaccines and oncolytic drugs, which are being transforming by the Biological Target Diagnosis and Treatment Innovation Team leaded by Prof. Yongxiang Zhao, will make a great breakthrough in targeting tumor therapy.
Dr. Varticovski was born in Siberia, Russia, where she completed first year medical school. She continued training at the U. of Utah, Albany Medical College, and Hematology/Oncology at New England Medical Center, Boston, MA. After long-standing clinical and independent research as Associate Professor, she joined NCI in 2003. Her research focuses on drug development and epigenetic regulation in cancer. She is Board-certified in Internal Medicine and Hematology/Oncology and has over 100 peer-reviewed publications. Dr. Varticovski has a long-standing involvement in education of Russian-speaking medical professionals and is the Founding Director of first Russian American Medical Association in USA.